

Correction to NOSTRA Investigators

DOI:
[10.1186/s13063-020-4107-8](https://doi.org/10.1186/s13063-020-4107-8)

License:
Creative Commons: Attribution (CC BY)

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (Harvard):
NOSTRA Investigators 2020, 'Correction to: Ronopterin (VAS203) in patients with moderate and severe traumatic brain injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study', *Trials*, vol. 21, no. 1, 172. <https://doi.org/10.1186/s13063-020-4107-8>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

CORRECTION

Open Access



Correction to: Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study

Frank Tegtmeier¹, Reinhard Schinzel^{1*}, Ronny Beer², Diederik Bulters³, Jean-Yves LeFrant⁴, Joan Sahuquillo⁵, Andreas Unterberg⁶, Peter Andrews⁷, Antonio Belli⁸, Javier Ibanez⁹, Alfonso Lagares¹⁰, Michael Mokry¹¹, Harald Willschke¹², Charlotte Flüh¹³, Erich Schmutzhard² and on behalf of the NOSTRA Investigators

Correction to: *Trials* (2020) 21:80
<https://doi.org/10.1186/s13063-019-3965-4>

After publication of our article [1] the authors have notified us that one of the names has been incorrectly spelled.

- Original name spelling:
Charlotte Flühe
- Correct name spelling:
Charlotte Flüh

The original article has been corrected.

Published online: 12 February 2020

Reference

1. Tegtmeier, et al. Efficacy of Ronopterin (VAS203) in Patients with Moderate and Severe Traumatic Brain Injury (NOSTRA phase III trial): study protocol of a confirmatory, placebocontrolled, randomised, double blind, multi-centre study. *Trials*. 2020;21:80. <https://doi.org/10.1186/s13063-019-3965-4>.

Author details

¹vasopharm GmbH, Würzburg, Germany. ²Medizinische Universität Innsbruck, Innsbruck, Austria. ³Wessex Neurological Centre University Hospital, Southampton, UK. ⁴Hopital Universitaire Caremeau, Nimes, France. ⁵Vall d'Hebron University Hospital, Barcelona, Spain. ⁶Universitätsklinikum Heidelberg, Heidelberg, Germany. ⁷Western General Hospital Lothian University, Edinburgh, UK. ⁸Queen Elizabeth Hospital, Birmingham, UK. ⁹Espases University Hospital, Palma de Mallorca, Spain. ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain. ¹¹LKH – Universitätsklinikum Graz, Graz, Austria. ¹²Medizinische Universität Wien, Wien, Austria. ¹³Universitätsklinikum Schleswig-Holstein, Kiel, Germany.

The original article can be found online at <https://doi.org/10.1186/s13063-019-3965-4>

* Correspondence: schinzel@vasopharm.de

¹vasopharm GmbH, Würzburg, Germany

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.